Olanzapine/ samidorphan (Lybalvi)
Small molecule
Also known as ALKS 3831
Evidence outlook
Approved: Schizophrenia, Bipolar Disorder
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02634346 NCT02634346 · Schizophrenia This was a randomized, quadruple-blind, placebo- and active-controlled trial with 403 enrolled participants, including 134 assigned to ALKS 3831. The primary clinical symptom endpoint, change in PANSS total score at Week 4, favored ALKS 3831 over placebo and was statistically significant (p<0.001). Registry: NCT02634346 | 3 | Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 (4 weeks) 2017-05-25 | Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 (4 weeks): ALKS 3831 -23.9 units on a scale (Standard Error 1.28) vs Olanzapine -22.8 units on a scale (Standard Error 1.29) vs Placebo -17.5 units on a scale (Standard Error 1.32) | Reliable signal | link ↗ |
View 4 more trials
NCT02669758 NCT02669758 · Schizophrenia The study was an open-label, single-arm continuation of the randomized antecedent ALK3831-A305 trial, with 277 treated participants and no comparator group. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants With Adverse Events (AEs)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak. Registry: NCT02669758 | 3 | Number of Participants With Adverse Events (AEs) (Up to 52 weeks) 2018-06-29 | Number of Participants With Adverse Events (AEs) (Up to 52 weeks): ALKS 3831 136 Participants | Weak signal | link ↗ |
NCT03187769 NCT03187769 · Schizophrenia, Schizophreniform Disorders, Bipolar I Disorder This was a randomized, quadruple-blind, active-controlled trial with 426 participants, comparing ALKS 3831 to olanzapine. The primary outcome was a direct clinical measure, percent change in body weight at 12 weeks, which was met: the ALKS 3831 group gained significantly less weight (4.91% vs 6.77%, p=0.012). The trial was adequately powered and the result was clearly favorable for the experimental arm. Registry: NCT03187769 | 3 | Percent Change From Baseline in Body Weight at Week 12 (Baseline and 12 weeks) 2021-12-01 | Percent change from baseline in body weight at Week 12: 4.91% ALKS 3831 vs 6.77% olanzapine; least-squares mean difference −1.87 percentage points (95% CI −3.33 to −0.41; p=0.012). | Reliable signal | link ↗ |
NCT03201757 NCT03201757 · Schizophrenia, Schizophreniform Disorder, Bipolar I Disorder The study was an open-label, single-arm extension enrolling 523 participants who continued from ALK3831-A304, ALK3831-A306, or ALK3831-A307, so it provides long-term follow-up but cannot compare treatment with placebo or another therapy. Its clinical CGI-S outcome was reported descriptively, without a between-group primary endpoint test. Registry: NCT03201757 | 3 | Incidence of Adverse Events (Up to 48 months); Change From Baseline in Clinical Global Impression-Severity (CGI-S) Scale (Up to 48 months) 2023-09-06 | Incidence of Adverse Events (Up to 48 months): ALKS 3831 314 Participants | Partial signal | link ↗ |
NCT02694328 NCT02694328 · Schizophrenia This was a randomized, quadruple-blind trial against olanzapine alone in 561 adults, and both primary weight endpoints at Week 24 were met with statistical significance (p=0.003 for each). A sample-size calculation planned 400 randomized participants for at least 90% power, and 561 were enrolled. Registry: NCT02694328 | 3 | Percent Change From Baseline in Body Weight at Week 24 (Baseline and Week 24); Percentage of Participants With >/= 10% Weight Gain at Week 24 (Baseline and Week 24) 2018-11-07 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (1)
What this study did
Phase 1 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Bipolar Disorder: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Olanzapine / Samidorphan (Lybalvi): this drug | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist); mu-opioid receptor (antagonist) | Reliable signal | No reviewed efficacy summary in this indication | |
| Aripiprazole (Abilify Maintena) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D2/D3 and serotonin 5-HT1A receptor, Dopamine D2 receptor (partial agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Aripiprazole (Abilify) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Asenapine | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Cariprazine (Vraylar) | Approved | Small molecule | Dopamine D3/D2 receptor (partial agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Divalproex Sodium (Depakote ER) | Approved | Small molecule | GABAergic neurotransmission | not yet graded | No reviewed efficacy summary in this indication | |
| Divalproex Sodium (Depakote) | Approved | Small molecule | GABAergic neurotransmission | Partial signal | Featured results are non-efficacy only in this race | |
| Iloperidone (Fanapt) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Lamotrigine | Approved | Small molecule | Voltage-gated sodium channel | not yet graded | No reviewed efficacy summary in this indication | |
| Milsaperidone (VHX-896) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | Weak signal | No reviewed efficacy summary in this indication | |
| Olanzapine (Zyprexa) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Quetiapine (Seroquel XR) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Quetiapine (Seroquel) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Risperidone (Risperdal Consta) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Risperidone (Risperdal) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Risperidone (Rykindo) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Risperidone (Uzedy) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Ziprasidone | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Dexmedetomidine (Igalmi) | Phase 3 | Small molecule | Alpha-2 adrenergic receptor (agonist) | Reliable signal | No reviewed efficacy summary in this indication | |
| Loxapine (Adasuve) | Phase 3 | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | Partial signal | No reviewed efficacy summary in this indication | |
| Xanomeline / Trospium Chloride (Cobenfy) | Phase 3 | Small molecule | Muscarinic M1/M4 receptor (agonist/antagonist combination) | not yet graded | No reviewed efficacy summary in this indication | |
| ALTO-100 | Phase 2 | Small molecule | First-in-class oral small molecule neural plasticity enhancer | not yet graded | No reviewed efficacy summary in this indication | |
| Brenipatide | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Elunetirom | Phase 2 | Small molecule | Thyroid hormone receptor-beta | not yet graded | No reviewed efficacy summary in this indication | |
| Icalcaprant | Phase 2 | Small molecule | Kappa-opioid receptor (inhibitor) | not yet graded | No reviewed efficacy summary in this indication | |
| Lithium Salicylate / L-Proline (AL001) | Phase 1/2 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-1042 | Phase 1(overall) | Small molecule | Muscarinic M4 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Aripiprazole (Abilify MyCite) | Discontinued | Combination | Dopamine D2 and serotonin 5-HT1A receptors (partial agonist); serotonin 5-HT2A receptor (antagonist) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Olanzapine/samidorphan (Lybalvi) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.